推荐产品
等級
pharmaceutical primary standard
API 家族
eicosapentaenoic acid
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
形式
neat
運輸包裝
wet ice
儲存溫度
−20°C
SMILES 字串
O(CC)C(=O)\C=C\C=C\C=C\C=C\C=C\CCCCCCCCC
InChI
1S/C22H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h12-21H,3-11H2,1-2H3/b13-12+,15-14+,17-16+,19-18+,21-20+
InChI 密鑰
DTEMJWLYSQBXEL-MBFZXKRTSA-N
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Eicosapentaenoic acid ethyl ester EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Abbie L Cawood et al.
Atherosclerosis, 212(1), 252-259 (2010-06-15)
To examine n-3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques and the association with plaque inflammation and stability. Patients awaiting carotid endarterectomy (n=121) were randomised to consume control capsules or n-3 PUFA ethyl ester capsules until surgery (median 21
Eun Young Park et al.
Journal of agricultural and food chemistry, 53(21), 8334-8341 (2005-10-13)
The effects of the addition of amino acids and peptides on the oxidation of eicosapentaenoic acid ethyl ester (EPE) encapsulated by maltodextrin (MD) were investigated. The encapsulated lipid was prepared in two steps, that is, by mixing of EPE with
Agnes K Ayton et al.
Prostaglandins, leukotrienes, and essential fatty acids, 71(4), 205-209 (2004-08-11)
Anorexia nervosa (AN) carries the highest risk of morbidity and mortality amongst psychiatric disorders. The efficacy of current treatment approaches is limited. Despite the fat-phobic nature of the disease, poly-unsaturated fatty acids (PUFAs) have not received much research attention. Patients
Terry A Jacobson
Expert review of cardiovascular therapy, 10(6), 687-695 (2012-08-17)
ω-3 fatty acids reduce triglyceride (TG) levels, but corresponding increases in low-density lipoprotein cholesterol (LDL-C) levels may compromise achievement of lipid goals in patients with elevated cardiovascular risk. AMR101 is an investigational agent containing ≥96% of pure icosapent ethyl (the
Christie M Ballantyne et al.
The American journal of cardiology, 110(7), 984-992 (2012-07-24)
AMR101 is an ω-3 fatty acid agent containing ≥96% pure icosapent-ethyl, the ethyl ester of eicosapentaenoic acid. The efficacy and safety of AMR101 were evaluated in this phase 3, multicenter, placebo-controlled, randomized, double-blinded, 12-week clinical trial (ANCHOR) in high-risk statin-treated
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持